Enhancing and Quantitative Characterization of the Efficacy, Safety and Therapeutic Value of Multicomponent Anticancer Combinations Adjunct to Proton Therapy

Abstract

Increase of biological effectiveness and safety of proton therapy is an acute need of the current day. Combination therapy of cancer, often called the “cornerstone” of tumor treatment, effectively affects various pathways and mechanisms playing important role in affecting malignant cell induction, proliferation and tumor growth. Used as an adjuvant modality it can play a crucial role in enhancing the efficacy and therapeutic window of proton therapy. The reported research is aimed to maximize anticancer efficacy and safety of rubidium chloride, gemcitabine and DMSO combinations with various amounts of copper oxide nanoparticles and to characterize them in terms of specific selectivity and therapeutic value. FDA approved gemcitabine, DMSO, alkali metal salt RbCl solutions and copper oxide nanoparticle water and saline dispersions were selected as the most promising and secure components for the anticancer mixtures. Tessting results have clearly shown that additionof the nano-sized copper oxide can drastically increase the  selectivity, efficacy, safety and the therapeutic value of anticancer combinations due to synergistic interaction with gemcitabine and DMSO. We consider that the combinations of the approved anticancer drugs with alkali metal salt solutions and metal/metal oxide dispersion can serve as highly effective and save adjuvant modalities for enhancing the efficacy proton therapy. Probing of various new anticancer drugs, alternative anticancer agents, ionophores and nano-sized components is highly recommended